2017
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith LM, Zhu R, Strittmatter SM. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. Neuropharmacology 2017, 130: 54-61. PMID: 29191754, PMCID: PMC5743608, DOI: 10.1016/j.neuropharm.2017.11.042.Peer-Reviewed Original ResearchConceptsAlzheimer's modelDisease-modifying effectsDisease-modifying therapiesMouse Alzheimer’s modelsTherapy withdrawalAPPswe/Investigational agentsSynapse densityDrug washoutTransgenic modelAlzheimer's diseasePersistent benefitsPersistent improvementSaracatinibFyn inhibitorMemantineLoss of benefitDiseaseSpatial memoryMemory functionWashoutTherapySymptomsMiceWeeks
2014
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Strittmatter SM. Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nature Medicine 2014, 20: 590-591. PMID: 24901567, PMCID: PMC4371131, DOI: 10.1038/nm.3595.Peer-Reviewed Original ResearchFyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer's Research & Therapy 2014, 6: 8. PMID: 24495408, PMCID: PMC3978417, DOI: 10.1186/alzrt238.Peer-Reviewed Original ResearchAlzheimer's diseasePathogenesis of ADTreatment of ADPhase Ib studyLate-stage clinical testingUnique therapeutic targetMajor pathologic hallmarkDevastating neurodegenerative disorderPathologic hallmarkNovel therapiesIb studyTherapeutic strategiesTherapeutic targetSmall molecule inhibitorsClinical testingTyrosine kinase FynCellular prion proteinNeurodegenerative disordersDiseaseAβ oligomersCell surface bindingMultisite studyHigh potencyMolecule inhibitorsTherapy